For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Apnimed Plans $160 Million IPO for Sleep Apnoea Treatment Development

Jul 28, 2026
Apnimed Plans $160 Million IPO for Sleep Apnoea Treatment Development

Apnimed is set to launch an initial public offering () on the Nasdaq, aiming to raise up to $160 million to support the development of its innovative therapy for obstructive sleep apnoea (OSA). The company, based in Massachusetts, plans to offer 10 million shares priced between $14 and $16 each, with the possibility of increasing this amount by an additional 1.5 million shares, potentially generating an extra $24 million depending on underwriter interest.

The funds raised from the IPO will primarily be allocated to advancing Apnimed's lead candidate, oxnimbi, also known as AD109, which is designed to enhance muscle activity in the upper airways to prevent airway collapse during sleep. Apnimed intends to dedicate approximately $228.8 million from the IPO and existing resources to support the regulatory process and commercialization efforts for oxnimbi. Additionally, some of the IPO proceeds will be used to fund research and development activities for other drug candidates.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

Currently, oxnimbi is under review by the U.S. Food and Drug Administration (), which is expected to make a decision on its approval by February 28, 2027, based on positive data from the drug's Phase III . While there are various device-based treatments available for OSA, many patients are either ineligible for or unwilling to use continuous positive airway pressure (CPAP) machines, which are designed to keep airways open during sleep.

If approved, oxnimbi would be the first oral therapy available for OSA, a market that has seen limited pharmaceutical options until recently. In 2024, Eli Lilly's weight loss drug, (tirzepatide), became the first medication to receive approval for OSA, providing a new treatment avenue for obese patients. However, a review published in Sleep Medicine noted that only about one-third of OSA patients are clinically obese, indicating a significant portion of patients may not benefit from Zepbound.

By introducing a treatment suitable for all types of OSA, regardless of a patient's weight, Apnimed aims for oxnimbi to become a leading option in the market, which currently affects approximately 936 million individuals globally. Apnimed's CEO, Larry Miller, expressed optimism about the potential of oxnimbi to reshape the sleep apnoea treatment landscape and create significant commercial opportunities for the company.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Anthropic Sets IPO Price Ahead of Nasdaq Trading Debut
Breaking Market News Nov 16, 2026

Anthropic Sets IPO Price Ahead of Nasdaq Trading Debut

Anthropic, known for its AI models, is set to price its initial public offering on Wednesday, with trading starting on Thursday under the…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)